EP1161536A1 - Proteines humaines a domaines hydrophobes et adn codant pour ces proteines - Google Patents

Proteines humaines a domaines hydrophobes et adn codant pour ces proteines

Info

Publication number
EP1161536A1
EP1161536A1 EP99972227A EP99972227A EP1161536A1 EP 1161536 A1 EP1161536 A1 EP 1161536A1 EP 99972227 A EP99972227 A EP 99972227A EP 99972227 A EP99972227 A EP 99972227A EP 1161536 A1 EP1161536 A1 EP 1161536A1
Authority
EP
European Patent Office
Prior art keywords
protein
present
amino acid
sequences
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99972227A
Other languages
German (de)
English (en)
Inventor
Seishi Kato
Tomoko Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagami Chemical Research Institute
Protegene Inc
Original Assignee
Sagami Chemical Research Institute
Protegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP32625598A external-priority patent/JP2007222001A/ja
Application filed by Sagami Chemical Research Institute, Protegene Inc filed Critical Sagami Chemical Research Institute
Publication of EP1161536A1 publication Critical patent/EP1161536A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • Fig. 40 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10663.
  • Fig. 41 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP03165.
  • Fig. 48 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10673.
  • tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II chain protein and an MHC class II /3 chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II chain protein and an MHC class II /3 chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • a protein of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
  • Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints.
  • De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
  • a protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes.
  • Proteins of the present invention may also exhibit anti-inflammatory activity.
  • the anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell- cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.
  • ⁇ HP10636> (SEQ ID NOS: 66, 76, and 86) Determination of the whole base sequence of the cDNA insert of clone HP10636 obtained from cDNA library of human fibrosarcoma cell line HT-1080 revealed the structure consisting of a 179-bp 5 ' -untranslated region, a 1278-bp ORF, and a 255-bp 3 '-untranslated region.
  • the ORF encodes a protein consisting of 425 amino acid residues and there existed ten putative transmembrane domains.
  • Figure 26 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of high molecular weight.
  • the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. R09702) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
  • Table 26 shows the comparison between amino acid sequences of the human protein of the present invention (HS) and the Schizosaccharomyces pombe hypothetical protein (SP) .
  • the marks of -, *, and . represent a gap, an amino acid residue identical with that of the protein of the present invention, and an amino acid residue similar to that of the protein of the present invention, respectively.
  • the both proteins shared a homology of 43.4% in the entire region.
  • the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. AA043039) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
  • ⁇ HP10665> (SEQ ID NOS: 124, 134, and 144) Determination of the whole base sequence of the cDNA insert of clone HP10665 obtained from cDNA library of human fibrosarcoma cell line HT-1080 revealed the structure consisting of a 31-bp 5' -untranslated region, a 744-bp ORF, and a 142-bp 3'-untranslated region.
  • the ORF encodes a protein consisting of 247 amino acid residues and there existed a putative secretory signal at the N-terminus.
  • Figure 44 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein.
  • the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. R96413) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
  • the present invention also provides genes corresponding to the polynucleotide sequences disclosed herein.
  • “Corresponding genes” are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5 ' and 3 ' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein.
  • the present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein.
  • stringency conditions are shown in the Table 32 below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des protéines humaines à domaines hydrophobes, des ADN codant pour ces protéines et des vecteurs d'expression pour ces ADN, ainsi que des cellules eucaryotiques exprimant ces ADN.
EP99972227A 1998-11-17 1999-11-17 Proteines humaines a domaines hydrophobes et adn codant pour ces proteines Withdrawn EP1161536A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP32625598 1998-11-17
JP32625598A JP2007222001A (ja) 1998-11-17 1998-11-17 疎水性ドメインを有するヒトタンパク質及びそれをコードするｄｎａ
JP36431598 1998-12-22
JP36431598 1998-12-22
JP6981199 1999-03-16
JP6981199 1999-03-16
JP11929999 1999-04-27
JP119299 1999-04-27
JP13816999 1999-05-19
JP13816999 1999-05-19
PCT/JP1999/006412 WO2000029448A2 (fr) 1998-11-17 1999-11-17 Proteines humaines a domaines hydrophobes et adn codant pour ces proteines

Publications (1)

Publication Number Publication Date
EP1161536A1 true EP1161536A1 (fr) 2001-12-12

Family

ID=27524206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99972227A Withdrawn EP1161536A1 (fr) 1998-11-17 1999-11-17 Proteines humaines a domaines hydrophobes et adn codant pour ces proteines

Country Status (3)

Country Link
EP (1) EP1161536A1 (fr)
AU (1) AU1181900A (fr)
WO (1) WO2000029448A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806581A1 (de) * 1998-02-17 1999-10-21 Forschungszentrum Juelich Gmbh Sequenzen eines Ih-Ionenkanals und deren Verwendung
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000050442A2 (fr) * 1999-02-26 2000-08-31 Millennium Pharmaceuticals, Inc. Proteines secretees et utilisations
AU4456800A (en) 1999-04-15 2000-11-02 Icagen, Inc. Human hac3
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
JP2003505350A (ja) * 1999-07-20 2003-02-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2001009162A2 (fr) * 1999-07-30 2001-02-08 Millennium Pharmaceuticals, Inc. Proteine secretees et leurs applications
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
KR20020062652A (ko) * 1999-12-09 2002-07-26 상꾜 가부시키가이샤 고지혈증의 치료 또는 예방제의 시험방법
WO2001098503A2 (fr) * 2000-06-21 2001-12-27 Bayer Aktiengesellschaft Regulation d'une enzyme de type serine protease 1 d'eosinophile humain
EP1409676A2 (fr) * 2001-03-07 2004-04-21 Andre Schuh Molecules d'acides nucleiques cd109, polypeptides et methodes d'utilisation associees
WO2002070738A2 (fr) 2001-03-07 2002-09-12 Andre Schuh Diagnostic et traitement des troubles sanguins
AU2002252885A1 (en) * 2001-04-24 2002-11-05 Mcgill University A 150 kda tgf-beta 1 accessory receptor acting as a negative modulator of tgf-beta signaling
EP1578364A4 (fr) * 2002-09-16 2011-06-08 Genentech Inc Compositions et methodes de traitement de maladies de nature immune
FR2849055A1 (fr) * 2002-12-18 2004-06-25 Exonhit Therapeutics Sa Nouvelle cible moleculaire de l'angiogenese et utilisations
JP2008522632A (ja) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列
JP4965326B2 (ja) * 2007-05-01 2012-07-04 独立行政法人科学技術振興機構 生理活性蛋白質の分泌を促進する新規な遺伝子ファミリー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092175A1 (en) * 1996-11-13 2003-05-15 Seishi Kato Human proteins having transmembrane domains and dnas encoding these proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0029448A3 *

Also Published As

Publication number Publication date
WO2000029448A2 (fr) 2000-05-25
WO2000029448A3 (fr) 2001-12-27
AU1181900A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
EP1254221A2 (fr) Proteines humaines a domaines hydrophobes et adn codant ces proteines
EP1100898A2 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
WO2000029448A2 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
WO2001012660A2 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
EP1196561A2 (fr) Proteines humaines ayant des domaines hydrophobes et adn codant pour ces proteines
WO1999043802A2 (fr) Proteines humaines possedant des domaines transmembranaires et adn codant ces proteines
WO2000000506A2 (fr) Proteines humaines possedant des domaines hydrophobes et adn codant ces proteines
WO2001004297A2 (fr) Proteines humaines a domaines hydrophobes et adn codant ces proteines
EP1005548A1 (fr) PROTEINES DU TYPE GALECTINES 9 HUMAINES ET ADNc CODANT CES PROTEINES
WO1999018204A2 (fr) PROTEINES HUMAINES COMPORTANT DES SEQUENCES DE SIGNAUX SECRETOIRES ET ADNc CODANT CES PROTEINES
AU1175199A (en) Human proteins having transmembrane domains and dnas encoding these proteins
WO1999018200A1 (fr) Proteines ressemblant au facteur h du complement humain et adnc codant ces proteines
AU9283298A (en) Human proteins having transmembrane domains and cdnas encoding these proteins
US6500939B1 (en) cDNAs coding for human proteins having transmembrane domains
EP1194543A2 (fr) PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT
WO1999018202A2 (fr) Proteines humaines comportant des domaines transmembranaires et adn codant ces proteines
EP1090131A1 (fr) Proteines humaines de type glycoprotease et adn codant ces proteines
US20040048339A1 (en) Human proteins having transmembrane domains and cDNAs encoding these proteins
EP1075516A2 (fr) Proteines humaines comportant des domaines transmembranaires et sequences d'adn codant ces proteines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

D17D Deferred search report published (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040416